Evaluación de la capacidad que tienen los niveles de ácido desoxirribonucleico libre circulante mitocondrial y nuclear urinario para discriminar muestras de sujetos con nefritis lúpica
datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
dc.contributor.advisor | Navarro, Elkin | |
dc.contributor.advisor | Navarro, Roberto | |
dc.contributor.author | Márquez Escobar, Olga Cecilia | |
dc.date.accessioned | 2022-08-01T16:07:18Z | |
dc.date.available | 2022-08-01T16:07:18Z | |
dc.date.issued | 2022 | |
dc.description.abstract | El lupus eritematoso sistémico (LES), es una enfermedad autoinmune, proclive a una presentación clínica heterogénea que debuta de manera silente en casos de nefritis lúpica activa (NLA), lo cual es mandatorio de una biopsia renal percutánea con consecuentes eventos adversos. Objetivo: Evaluar la capacidad que tienen los niveles de ADN libre circulante mitocondrial y nuclear urinario (uADN-lc) para discriminar muestras de sujetos con nefritis lúpica activa (NLA). Sujetos y Métodos: Se tomaron muestras de orina de (74) sujetos, (25) con LES sin compromiso renal, (12) con NLA (12) con NLR y (25) Controles sanos. Se realizó una reacción en cadena de la polimerasa en tiempo real (qPCR) para la cuantificación de las moléculas de ácido desoxirribonucleico libre circulante (ADN-lc), mediante el empleo de genes constitutivos ND1 (mitocondrial) y GAPDH (nuclear), a posteriori de su extracción urinaria (uADN-lc), mediante el Kit Comercial de Aislamiento con Perlas Magnéticas (Applied Biosystems), y la determinación de su concentración con espectrofotómetro (Nanodrop One 2000 de Thermo Scientific ®) y analizador de imágenes. | spa |
dc.description.abstract | Systemic lupus erythematous (SLE) is an autoimmune disease, prone to a heterogeneous clinical presentation that debuts silently in cases of active lupus nephritis (ALN), which is mandatory for a percutaneous renal biopsy with consequent adverse events. Objective: To evaluate the ability of mitochondrial and nuclear urinary cell-free DNA (cf-uDNA) levels to discriminate samples from subjects with active lupus nephritis (ALN). Subjects and Methods: Urine samples were taken from (74) subjects, (25) with SLE without kidney failure, (12) with (ALN), (12) with (RLN) and (25) Healthy Controls. A quantitative real-time polymerase chain reaction (Q-PCR) was performed for cell-free deoxyribonucleic acid molecule quantification (cf-DNA), using constitutive genes ND1 (mitochondrial) and GAPDH (nuclear), after their urinary extraction (cf-uDNA), by means of the Commercial Isolation Kit with Magnetic Pearls (Applied Biosystems), and its concentration measurement with spectrophotometer (Nanodrop One 2000 de Thermo Scientific ®) and image analyzer. | eng |
dc.format.mimetype | spa | |
dc.identifier.uri | https://hdl.handle.net/20.500.12442/10436 | |
dc.language.iso | spa | spa |
dc.publisher | Ediciones Universidad Simón Bolívar | spa |
dc.publisher | Facultad de Ciencias Básicas y Biomédicas | spa |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Complejos inmunes | spa |
dc.subject | Concentración de ácido desoxirribonucleico libre circulante urinario (uADN-lc) | spa |
dc.subject | GAPDH | spa |
dc.subject | SLEDAI | spa |
dc.subject | SLICC | spa |
dc.subject | ND1 | spa |
dc.subject | Nefritis lúpica activa (NLA) | spa |
dc.subject | Concentration of urinary circulating free deoxyribonucleic acid (uDNA-lc) | eng |
dc.subject | Active lupus nephritis (ANL) | eng |
dc.title | Evaluación de la capacidad que tienen los niveles de ácido desoxirribonucleico libre circulante mitocondrial y nuclear urinario para discriminar muestras de sujetos con nefritis lúpica | spa |
dc.title.translated | Assessment of the ability of mitochondrial and nuclear urinary cell free circulating deoxyribonucleic acid levels to discriminate samples from subjects with Lupus Nephritis | eng |
dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
dc.type.spa | Trabajo de grado máster | spa |
dcterms.references | Oparina N, Martínez-Bueno M, Alarcón-Riquelme ME. An update on the genetics of systemic lupus erythematosus. Current Opinion in Rheumatology. 2019; 31(6):659–68. | eng |
dcterms.references | Vaillant AAJ, Goyal A, Bansal P, Varacallo M. Systemic Lupus Erythematosus (SLE) - StatPearls - NCBI Bookshelf. StatPearls [Internet]. 2020. | eng |
dcterms.references | Musso CG, Terrasa S, Ciocchini M, Gonzalez-Torres H, Aroca-Martinez G. Looking for a better definition and diagnostic strategy for acute kidney injury: A new proposal. Vol. 117, Archivos Argentinos de Pediatria. Sociedad Argentina de Pediatria; 2019. p. 4–5. | eng |
dcterms.references | Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics. 2020; 16(1):19–30. | eng |
dcterms.references | Justiz Vaillant AA, Sabir Sarah, Jan Arif. Physiology, Immune Response - StatPearls - NCBI Bookshelf. 2020. | eng |
dcterms.references | Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PAN. Annals of the Rheumatic Diseases. 2018; 77(11):1549–57. | eng |
dcterms.references | Ahmadpoor P, Dalili N, Rostami M. An update on pathogenesis of systemic lupus erythematosus. Iranian journal of kidney diseases. 2014 May; 8(3):171–84. | eng |
dcterms.references | Alonso L, Naranjo G, María G, Duque V, Uribe OU, Alberto L, et al. Nefropatía lúpica: presentación clínica, clasificación y tratamiento. Revista Colombiana de Reumatologìa. 2006; 13(4):307-33. | spa |
dcterms.references | Latinoamérica DE, Depine SÁ, Aroca Martínez G. DESAFIANDO A LA INEQUIDAD. | spa |
dcterms.references | Sánchez E, Gómez LM, Lopez-Nevot MA, González-Gay MA, Sabio JM, Ortego-Centeno N, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes and Immunity. 2006;7(5):433–6. | eng |
dcterms.references | Hernández FR. Biopsia renal. Acta Pediátrica de México. 2009; 30(1):36–53. | spa |
dcterms.references | Pombas B, Rodríguez E, Sánchez J, Radosevic A, Gimeno J, Busto M, et al. Risk factors associated with major complications after ultrasound-guided percutaneous renal biopsy of native kidneys. Kidney and Blood Pressure Research. 2020; 45(1):122–30. | eng |
dcterms.references | Perez-Hernandez J, Martinez-Arroyo O, Ortega A, Galera M, Solis-Salguero MA, Chaves FJ, et al. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. Journal of Nephrology. 2020;(0123456789). | eng |
dcterms.references | Husi H, Human C. Molecular determinants of acute kidney injury. Journal of Injury and Violence Research. 2014; 7(2):75-86. | eng |
dcterms.references | Pacheco-Lugo L, Sáenz-García J, Navarro Quiroz E, González Torres H, Fang L, Díaz-Olmos Y, et al. Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. Lupus. 2019 Jan 1; 28(1):34–43. | eng |
dcterms.references | Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, et al. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases. 2020; 1-7. | eng |
dcterms.references | Truszewska A, Wirkowska A, Gala K, Truszewski P, Krzemień-Ojak Ł, Perkowska-Ptasińska A, et al. Cell-free DNA profiling in patients with lupus nephritis. Lupus. 2020; 0(0):1–14. | eng |
dcterms.references | Ding Y, Yu X, Wu L, Tan Y, Qu Z, Yu F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. Vol. 12, Frontiers in Immunology. 2021. | eng |
dcterms.references | Ramos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus. 2004 Oct 2; 13(10):777–83. | eng |
dcterms.references | López-Gómez JM, Rivera F. Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish registry of glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2008; 3(3):674–81. | eng |
dcterms.references | Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care and Research. 2018; 70(3):428–38. | eng |
dcterms.references | Sagheb MM, Namazi S, Geramizadeh B, Karimzadeh A, Oghazian MB, Karimzadeh I. Serum cystatin C as a marker of renal function in critically Ill patients with normal serum creatinine. Nephro-Urology Monthly. 2014; 6(2). | eng |
dcterms.references | Pathogens S. What is damaging the kidney in lupus nephritis? Nature reviews Rheumatology. 2016; 1848(3):3047–54. | eng |
dcterms.references | Oreskovic A, Brault ND, Panpradist N, Lai JJ, Lutz BR. Analytical Comparison of Methods for Extraction of Short Cell-Free DNA from Urine. Journal of Molecular Diagnostics. 2019; 21(6):1067–78. | eng |
dcterms.references | Moroni G, Quaglini S, Radice A, Trezzi B, Raffiotta F, Messa P, et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. Journal of Immunology Research. 2015; 2015. | eng |
dcterms.references | Potter B. The history of the disease called lupus. Journal of the History of Medicine and Allied Sciences. 1993; 48(1):80–90. | eng |
dcterms.references | Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology. 2020;16(10):565–79. | eng |
dcterms.references | Fortuna G, Brennan MT. Systemic lupus erythematosus. Epidemiology, pathophysiology, manifestations, and management. Dental Clinics of North America. 2013; 57(4):631–55. | eng |
dcterms.references | Alarcón GS, McGwin G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002; 11(2):95–101. | eng |
dcterms.references | Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discovery medicine. 2011 Dec; 12(67):535–45. | eng |
dcterms.references | Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nature Reviews Rheumatology. 2021; 17(9):515–32. | eng |
dcterms.references | Goulielmos GN, Zervou MI, Vazgiourakis VM, Ghodke-Puranik Y, Garyfallos A, Niewold TB. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018; 668(May):59–72. | eng |
dcterms.references | Nielsen CT. Circulating microparticles in systemic lupus erythematosus. Danish Medical Journal. 2012; 59(11):1–34. | eng |
dcterms.references | Javinani A, Ashraf-Ganjouei A, Aslani S, Jamshidi A, Mahmoudi M. Exploring the etiopathogenesis of systemic lupus erythematosus: a genetic perspective. Immunogenetics. 2019; 71(4):283–97. | eng |
dcterms.references | Zhan Y, Guo Y, Lu Q. Aberrant Epigenetic Regulation in the Pathogenesis of Systemic Lupus Erythematosus and Its Implication in Precision Medicine. Cytogenetic and Genome Research. 2016; 149(3):141–55. | eng |
dcterms.references | Rodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, et al. The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pacific journal of allergy and immunology. 2021; 39(4). | eng |
dcterms.references | Avaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clinical and Vaccine Immunology. 2007;1 4(5):505-9. | eng |
dcterms.references | Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: The central role of nucleosomes revealed. American Journal of Pathology. 2008; 172(2):275–83. | eng |
dcterms.references | Goropevšek A, Holcar M, Avčin T. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. Clinical Reviews in Allergy and Immunology. 2017; 52(2):164–81. | eng |
dcterms.references | Vahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, et al. STATs shape the active enhancer landscape of T cell populations. Cell. 2012; 151(5):981–93. | eng |
dcterms.references | Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, et al. Urinary, Plasma, and Serum Biomarkers’ Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis. American Journal of Kidney Diseases. 2015; 66(6):993–1005. | eng |
dcterms.references | Broza YY, Zhou X, Yuan M, Qu D, Zheng Y, Vishinkin R, et al. Disease Detection with Molecular Biomarkers: From Chemistry of Body Fluids to Nature-Inspired Chemical Sensors. Chemical Reviews. 2019; 119(22):11761–817. | eng |
dcterms.references | Kazumitsu Nawata MK. Imp. Global Facts_ About Kidney Disease - The National Kidney Foundation. Health, December 8, 2017; 2017. p. Vol.9 No.13. | eng |
dcterms.references | Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis & Rheumatism. 1992; 35(6):630–40. | eng |
dcterms.references | Margulis L. Genetic and evolutionary consequences of symbiosis. Experimental Parasitology. 1976; 39(2):277–349. | eng |
dcterms.references | Dye JR, Ullal AJ, Pisetsky DS. The Role of Microparticles in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus. Vol. 78, Scandinavian Journal of Immunology. 2013. p. 140–8. | eng |
dcterms.references | Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124: 71–81. | eng |
dcterms.references | Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Vol. 33, Current Opinion in Rheumatology. 2021. p. 197–204. | eng |
dcterms.references | Aronson JK, Ferner RE. Biomarkers—a general review. Current Protocols in Pharmacology. 2017; 2017(March):9.23.1-9.23.17. | eng |
dcterms.references | Gil Hernández F. El papel de los biomarcadores en Toxicología Humana. Revista de Toxicología. 2000; 17(1):19–26. | spa |
dcterms.references | Hosni ND, Anauate AC, Boim MA. Reference genes for mesangial cell and podocyte (qPCR) gene expression studies under high-glucose and renin-angiotensin-system blocker conditions. Vol. 16, PLoS ONE. 2021. | eng |
dcterms.references | Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death and Differentiation. 2009; 16(12):1573–81. | eng |
dcterms.references | Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. British Journal of Rheumatology. 1996; 35(3):248–54. | eng |
dcterms.references | Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatism. 1996; 39(3):363–9. | eng |
dcterms.references | Aringer M. Lupus Eritematoso Sistémico Criterios De Clasificación Eular/Acr 2019. American College of Rheumatology. 2019; 78(11):1151. | spa |
dcterms.references | Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Vol. 78, Annals of the Rheumatic Diseases. 2019. p. 736–45. | eng |
dcterms.references | Augustus E, van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE. 2020; 15(4):1-22. | eng |
dcterms.references | Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International. 2018; 93(4):789-96. | eng |
dcterms.references | Fu L, Wang YG. Robust regression with asymmetric loss functions. Statistical Methods in Medical Research. 2021; 30(8):1800-15. | eng |
dcterms.references | Thermo Scientific. NanoDrop 2000 / 2000c Spectrophotometer. Thermo scientific inc. 2000; 97. | eng |
dcterms.references | Mix M, Gels E gel GP, Mixes M. ∤ ∤ 0.2. | eng |
dcterms.references | Arnaud CH. Thermo fisher scientific. Vol. 84, Chemical and Engineering News. 2006. p. 11–5. | eng |
dcterms.references | Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020; 395(10225):709–33. | eng |
dcterms.references | ||
dcterms.references | Aroca-Martínez GJ, Mendoza-Jaimes J, Gonzalez-Torres HJ, Dominguez-Vargas A, Martinez-Bayona Á, Navarro-Quiroz E, et al. Consecutive renal biopsy in a cohort of patients with lupus nephritis of the Colombian caribbean. Journal of Nephropathology. 2018; 7(4):233–40. | eng |
dcterms.references | Programme EM, Commission T. Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine.: 1-2. | eng |
dcterms.references | Wagner JT, Kim HJ, Johnson-Camacho KC, Kelley T, Newell LF, Spellman PT, et al. Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples. Vol. 10, Scientific Reports. 2020. | eng |
dcterms.references | Ueda BR, Shiku H, Pfreundschuh M, Takahashi T, Li LTC, Whitmore WF, et al. CELL SURFACE ANTIGENS OF HUMAN RENAL C A N C E R D E F I N E D BY A U T O L O G O U S T Y P I N G *. 1979; 150(September):564–79. | eng |
dcterms.references | F YDRCJW. Distinct patterns and behavioural. World J Urolo; 2013. p. 21–9. | eng |
dcterms.references | Saetun P, Semangoen T, Thongboonkerd V. Characterizations of urinary sediments precipitated after freezing and their effects on urinary protein and chemical analyses. Vol. 296, American Journal of Physiology - Renal Physiology. 2009. | eng |
dcterms.references | Touma Z, Urowitz MB, Gladman DD. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. Journal of Rheumatology. 2013; 40(5):733. | eng |
dcterms.references | Quintana G, Coral-Alvarado P, Aroca G, Patarroyo PM, Chalem P, Iglesias-Gamarra A, et al. Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from active systemic lupus erythematosus. Autoimmunity Reviews. 2010 Sep; 9(11):750-5. | eng |
dcterms.references | Fernández D, Rincon-Riaño DN, Bernal-Macías S, Rosselli D. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia Burden of disease View project ANTI-DFS70 ANTIBODY View project. Available from: https://www.researchgate.net/publication/318967596. | spa |
dcterms.references | Navarro-Quiroz E, Pacheco-Lugo L, Lorenzi H, Díaz-Olmos Y, Almendrales L, Rico E, et al. High-throughput sequencing reveals circulating miRNAs as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. PLoS ONE. 2016 Nov 1; 11(11). | eng |
dcterms.references | Hsu B, Sherina V, McCall MN. Autoregressive modeling and diagnostics for (qPCR) amplification. Bioinformatics. 2020; 36(22–23):5386-91. | eng |
dcterms.references | Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013 Sep; 13(5):481-92. | eng |
dcterms.references | Berensmeier S. Magnetic particles for the separation and purification of nucleic acids. Vol. 73, Applied Microbiology and Biotechnology. 2006. p. 495–504. | eng |
dcterms.references | Neuberger EWI, Brahmer A, Ehlert T, Kluge K, Philippi KFA, Boedecker SC, et al. Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients. Scientific Reports. 2021; 11(1):1-11. | eng |
dcterms.references | Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Journal of Translational Medicine. 2018; 16(1):1-10. | eng |
dcterms.references | Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian Journal of Internal Medicine. 2013; 4(2):627-35. | eng |
dcterms.references | Parr RL, Martin LH. Mitochondrial and nuclear genomics and the emergence of personalized medicine. Human Genomics. 2012; 6(1):1-8. | eng |
dcterms.references | Ma H, Bell KN, Loker RN. (qPCR) and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies. Vol. 20, Molecular Therapy - Methods and Clinical Development. Cell Press; 2021. p. 152-68. | eng |
dcterms.references | Wang XS, Zhao MQ, Zhang L, Kong DJ, Ding XZ, Hu XC, Yang JQ GS. OTT-86908-urine-micrornas-as-biomarkers-for-bladder-cancer--a-diagnost _ Enhanced Reader. Am J Transl Res.; 2018. p. 1935-48. | eng |
dcterms.references | Chapman JR, Waldenström J. With reference to reference genes: A systematic review of endogenous controls in gene expression studies. PLoS ONE. 2015; 10(11):1-18. | eng |
dcterms.references | Tesis para obtener el grado de Doctor en Investigación y Docencia. | spa |
dcterms.references | Berensmeier S. Magnetic particles for the separation and purification of nucleic acids. Vol. 73, Applied Microbiology and Biotechnology. 2006. p. 495-504. | eng |
dcterms.references | Ponti G, Maccaferri M, Manfredini M, Kaleci S, Mandrioli M, Pellacani G, et al. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients. Clinica Chimica Acta. 2018 Apr 1; 479: 14-9. | eng |
dcterms.references | Caitlin M. Stewart, Prachi D Kothari, Florent Moulier, Richard Mair, Saira Somnay RB. The value of cell‐free DNA for molecular pathology _ Enhanced Reader. New York; | eng |
dcterms.references | Patricia Valda Toro, Bracha Erlanger BHP. Comparison of Cell Stabilizing Blood Collection Tubes for Circulating Plasma Tumor DNA. Sidney; 2015. p. 1–15. | eng |
dcterms.references | Liu B, Liu Y, Pan X, Li M, Yang S, Li SC. DNA methylation markers for pan-cancer prediction by deep learning. Genes. 2019; 10(10). | eng |
oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
sb.programa | Maestría en Genética | spa |
sb.sede | Sede Barranquilla | spa |